Delving into the Latest Updates on Hibernaid, Inc. with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	3
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Phase 1 First-in Human randomized, open-label, active control standard of care study of the safety of HBN-1 administered as pharmacologically induced hypothermia as an adjunct to standard of care targeted temperature management in adult patients who have experienced out-of-hospital-cardiac arrest. HBN-1 will be administered IV as a loading dose infusion followed by a 12-hour maintenance infusion.

Start Date30 Oct 2019

Sponsor / Collaborator

Hibernaid, Inc.

100 Clinical Results associated with Hibernaid, Inc.

Login to view more data

0 Patents (Medical) associated with Hibernaid, Inc.

Login to view more data

100 Deals associated with Hibernaid, Inc.

Login to view more data

100 Translational Medicine associated with Hibernaid, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 1 Clinical

Other

1

Login to view more data